Correlation of integrin β3 mRNA and vascular endothelial growth factor protein expression profiles with the clinicopathological features and prognosis of gastric carcinoma

Abstract

peritoneal metastasis, the mean MVD were significantly higher than those in patients of expanding type (P < 0.01), stage T1-T2 (P < 0.01), non-vessel invasion (P < 0.01), without lymphatic metastasis (P < 0.01), without hepatic and peritoneal metastasis (P < 0.01), respectively. It was found that the positive expression rate of integrin β3 mRNA was positively related to that of VEGF protein (P < 0.01) and MVD (P < 0.05), meanwhile the positive expression rate of VEGF protein was positively related to MVD (P < 0.05). The mean survival period in patients with positive expression of integrin β3 mRNA and VEGF, and MVD ≥ 54.9/mm 2 was significantly shorter than that in patients with negative expression of integrin β3 mRNA (P < 0.05) and VEGF (P < 0.01), and MVD < 54.9/mm 2 (P < 0.01). Five-year survival rate in patients with positive expression of integrin β3 mRNA and VEGF, and MVD ≥ 54.9/mm 2 was significantly lower than those with negative expression of integrin β3 mRNA (P < 0.05), VEGF (P < 0.05), and MVD < 54.9/mm 2 (P < 0.01). CONCLUSION:Integrin β3 and VEGF expression can synergistically enhance tumor angiogenesis, and may play a crucial role in invasion and metastasis of gastric carcinoma. Therefore, they may be prognostic biomarkers and novel molecular therapeutic targets. INTRODUCTIONGastric cancer is the leading cause of death in China. Abstract AIM: To investigate integrin β3 mRNA and vascular endothelial growth factor (VEGF) protein expression in gastric carcinoma, and its correlation with microvascular density, growth-pattern, invasion, metastasis and prognosis. METHODS: In situ hybridization (ISH) of integrin β3mRNA and immunohistochemistry of VEGF and CD34 protein were performed on samples from 118 patients with gastric cancer. RESULTS:The positive rate of integrin β3 mRNA in nontumor gastric mucosa (20%) was significantly lower than that of the gastric cancer tissue (52.5%, χ 2 = 10.20,

Integrin αvβ3-Targeted Radioimmunotherapy of Glioblastoma Multiforme

“…6). As seen in our study, the strong correlation of 18 F-FLT and Ki67 findings have been previously reported as prognostic indicators for malignant brain tumors (45).…”

“…Treatment animals showed a statistically significant reduction in 18 F-FLT signal intensity, indicating decreased cellular proliferation and tumor expansion (Figs. 4A and 5A).…”

“…The ability to noninvasively characterize tumor integrin expression, vascular permeability, and proliferation will allow for more accurate patient selection, monitoring, and therapeutic intervention. In the case of glioblastoma multiforme, 18 F-FDG has shown poor specificity in characterizing size, functional activity, and heterogeneity of primary and recurrent brain tumors due to the high basal glucose metabolic rate of normal brain tissue. Specifically, 18 F-FDG uptake of low-grade tumors is similar to that of normal white matter, and high-grade tumor uptake may approximate normal gray matter, decreasing the sensitivity of tumor detection (45).…”

“…In the case of glioblastoma multiforme, 18 F-FDG has shown poor specificity in characterizing size, functional activity, and heterogeneity of primary and recurrent brain tumors due to the high basal glucose metabolic rate of normal brain tissue. Specifically, 18 F-FDG uptake of low-grade tumors is similar to that of normal white matter, and high-grade tumor uptake may approximate normal gray matter, decreasing the sensitivity of tumor detection (45). FLT-based small-animal PET imaging is more sensitive for intracranial malignancies due to its inability to cross the blood-brain barrier (BBB) and thus reduce nonspecific uptake (46).…”

“…Small-animal PET imaging was used to characterize the in vivo treatment efficacy. 18 F-FDG and 18 F-FLT radiotracers were used to quantify tumor cell metabolic activity and DNA synthesis, respectively.…”